The global functional genomics market was valued at USD 13.62 billion in 2025. The market is estimated at USD 14.94 billion in 2026 and is projected to reach USD 37.85 billion by 2036, at a CAGR of 9.7% during the forecast period 2026-2036. This report provides a detailed assessment of the market, covering sequencing, CRISPR, RNAi, single-cell, and epigenomic technologies, government programs, biosafety and data policies, acquisitions, pricing, and the supplier landscape.
The market covers kits and reagents, instruments, software, and services used to find out how genes and genetic variants shape the behavior of cells and organisms. Researchers track gene expression and regulation and switch genes off or on with tools ranging from bulk and single-cell RNA sequencing, epigenomic assays, and quantitative PCR (qPCR) to arrays, CRISPR screening, and RNA interference (RNAi). Products include sequencing and library reagents, guide RNA libraries and nucleases, RNAi libraries, single-cell kits, instruments, analysis software, and outsourced services. Clinical diagnostics, therapeutic gene editing, variant-only sequencing, and proteomics are excluded.
With USD 42.5 million committed for an initial five years, the MorPhiC program of the National Human Genome Research Institute (NHGRI), part of the NIH, has begun a pilot covering 1,000 protein-coding genes as a first step toward defining what every human gene does. Industry is working at even larger scale: Illumina's Billion Cell Atlas, launched in January 2026, profiles 1 billion cells across more than 200 disease-relevant cell lines in which each of the 20,000 human genes is perturbed by CRISPR. It is the opening phase of a 5 billion cell atlas planned over three years, counts AstraZeneca, Merck, and Eli Lilly as founding partners, and is expected to yield about 20 petabytes of data within a year.
Genome-wide CRISPR and single-cell perturbation studies are expensive, which limits their use by smaller academic laboratories, early-stage biotechnology firms, and institutions in emerging economies that often fall back on targeted screens or outsourcing. Academic budgets are under pressure, with tools makers such as Bruker and Quanterix reporting soft U.S. academic demand in 2026, which can delay instrument purchases and large projects. Data handling is a major challenge, since petabyte-scale datasets need accelerated processing, cloud infrastructure, and bioinformatics skills that many laboratories lack. Screening results can also vary with cell models, guide design, and analysis methods, off-target effects can create false positives, and findings in cell lines do not always carry over to human biology.
Services and data products offer a significant opportunity, as many drug developers would rather buy large screening and single-cell datasets than build the capability in house; the Billion Cell Atlas is the first data product of Illumina's BioInsight business. Variant-to-function work is another opening, as base editing screens, saturation genome editing, and massively parallel reporter assays can test thousands of variants of uncertain significance at once. Cell and gene therapy developers use CRISPR screens to improve the persistence, potency, and safety of engineered cells, and research spending in China, Japan, South Korea, Singapore, and India is rising. Key trends include the scaling of single-cell studies to billions of cells, consolidation among single-cell and CRISPR technology providers, and the use of perturbation data to train predictive AI models.
By offering, the functional genomics market is segmented into kits & reagents, instruments, software & bioinformatics, and services. Kits & reagents are expected to account for the largest share in 2026, as reagents, guide and RNAi libraries, and single-cell and PCR kits are used up in every experiment, and a large installed base of sequencers and PCR systems keeps reagent demand recurring. Services are expected to grow at the highest CAGR, driven by the outsourcing of large CRISPR and single-cell studies, high-capacity offerings such as the Parse Biosciences GigaLab, and the launch of data products such as the Billion Cell Atlas. Software & bioinformatics is also set for strong growth as datasets get larger and AI tools enter routine analysis.
By technology, the functional genomics market is segmented into next-generation sequencing (NGS), PCR & qPCR, microarrays, CRISPR-based technologies, RNA interference (RNAi), and other technologies. NGS is set to hold the largest share in 2026, as RNA sequencing, single-cell sequencing, and epigenomic profiling all depend on it and sequencing is the readout for most large CRISPR and perturbation screens. CRISPR-based technologies are expected to grow at the highest CAGR, supported by wider use of genome-wide knockout, interference, and activation screens, single-cell perturbation projects such as the Billion Cell Atlas, and base and prime editing for variant-level studies. RNAi and microarrays are expected to grow more slowly as researchers move to CRISPR and sequencing-based methods.
By technique, the functional genomics market is segmented into gene expression profiling, genetic perturbation screening, epigenomic profiling, single-cell functional genomics, and other techniques. Gene expression profiling is expected to account for the largest share in 2026, given the broad use of RNA sequencing and qPCR in basic research, drug discovery, and biomarker work, and the role of qPCR in validating expression changes. Single-cell functional genomics is expected to grow at the highest CAGR, driven by studies that now reach millions and billions of cells, the pairing of single-cell readouts with CRISPR perturbations, and consolidation such as QIAGEN's agreement to buy Parse Biosciences and 10x Genomics' agreement to buy Scale Biosciences. Epigenomic profiling shows how gene regulation shifts in cancer and immune disease.
By application, the functional genomics market is segmented into drug discovery & target validation, disease mechanism research, biomarker discovery, cell & gene therapy development, agricultural & synthetic biology research, and other applications. Drug discovery & target validation is expected to account for the largest share in 2026, as drug developers rely on functional genomics to find and confirm targets and explain how drugs work, as the drug company backing of the Billion Cell Atlas shows. Cell & gene therapy development is expected to grow at the highest CAGR, supported by CRISPR screens that improve engineered cell therapies, transcriptomic characterization of cell products, and a growing therapy pipeline. The same tools help improve crops and microbial strains.
By end user, the functional genomics market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, contract research organizations, and other end users. Academic & research institutes are expected to account for the largest share in 2026, as universities, research institutes, and government programs such as MorPhiC carry out much of the field's research. Pharmaceutical & biotechnology companies are expected to grow at the highest CAGR, driven by target work, AI-led discovery, and cell and gene therapy programs, while funding pressure is expected to slow growth in the academic segment. CROs gain as more screening work is outsourced.
North America is set to hold the largest share of the functional genomics market in 2026, owing to strong public and private research funding, leading research institutions and genome centers, a dense base of drug developers, and home-based suppliers such as Illumina, 10x Genomics, Thermo Fisher Scientific, Bio-Rad Laboratories, Integrated DNA Technologies, and Agilent Technologies. In the U.S., demand is supported by programs such as MorPhiC and industry projects such as the Billion Cell Atlas, although weaker academic funding may slow near-term growth, while Canada adds demand through academic genomics and a growing AI drug discovery sector. Europe holds a significant share, supported by strong academic research, large pharmaceutical companies, and suppliers such as Merck KGaA and QIAGEN; the U.K. stands out for its genome research centers and pharmaceutical R&D, and Germany, Switzerland, France, the Netherlands, Sweden, and Denmark also contribute.
Asia-Pacific is projected to post the highest CAGR through 2036, owing to rising R&D spending, growing biopharmaceutical industries, national precision medicine programs, and local service and reagent suppliers. China is expected to hold the largest share in the region, helped by heavy life science investment and a large services base, while Japan, home to Takara Bio, is a key market for expression and editing tools, and South Korea, Singapore, Australia, and India are set for strong growth. Latin America, led by Brazil and Mexico, and the Middle East & Africa, where Saudi Arabia, the UAE, and Qatar run genomic medicine programs, hold smaller shares.
The functional genomics market is moderately consolidated, as large life science tools companies with sequencing, PCR, and reagent portfolios compete with specialists in CRISPR tools, single-cell platforms, analysis software, and services. Competition centers on throughput, cost per cell or sample, data quality, the range of reagents and libraries, end-to-end workflows, software and AI capabilities, and global support. Recent developments include 10x Genomics' August 2025 agreement to acquire Scale Biosciences, the July 2025 purchase of Synthego by funds managed by Perceptive Advisors, QIAGEN's November 2025 agreement to acquire Parse Biosciences, the January 2026 launch of the Illumina Billion Cell Atlas, and the April 2026 launch of the 10x Genomics Atera spatial biology platform.
Key companies profiled in the report include Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), QIAGEN N.V. (Netherlands), Bio-Rad Laboratories, Inc. (U.S.), 10x Genomics, Inc. (U.S.), Revvity, Inc. (U.S.), Merck KGaA (Germany), Danaher Corporation (Integrated DNA Technologies) (U.S.), Takara Bio Inc. (Japan), and GenScript Biotech Corporation (China).
The market covers kits and reagents, instruments, software, and services used to find out how genes and genetic variants shape the behavior of cells and organisms. Researchers track gene expression and regulation and switch genes off or on with tools ranging from bulk and single-cell RNA sequencing, epigenomic assays, and quantitative PCR (qPCR) to arrays, CRISPR screening, and RNA interference (RNAi). Products include sequencing and library reagents, guide RNA libraries and nucleases, RNAi libraries, single-cell kits, instruments, analysis software, and outsourced services. Clinical diagnostics, therapeutic gene editing, variant-only sequencing, and proteomics are excluded.
With USD 42.5 million committed for an initial five years, the MorPhiC program of the National Human Genome Research Institute (NHGRI), part of the NIH, has begun a pilot covering 1,000 protein-coding genes as a first step toward defining what every human gene does. Industry is working at even larger scale: Illumina's Billion Cell Atlas, launched in January 2026, profiles 1 billion cells across more than 200 disease-relevant cell lines in which each of the 20,000 human genes is perturbed by CRISPR. It is the opening phase of a 5 billion cell atlas planned over three years, counts AstraZeneca, Merck, and Eli Lilly as founding partners, and is expected to yield about 20 petabytes of data within a year.
Market Dynamics
Drug target discovery and validation is a major driver of the functional genomics market, as drug developers want stronger proof that acting on a target will change disease before they commit to a program, and screens reveal essential disease genes, resistance mechanisms, and the effects of variants flagged by human genetics. CRISPR knockout, interference, and activation screens, especially when paired with single-cell readouts in Perturb-seq designs, generate far richer data but need many more cells, guide libraries, and sequencing runs. Falling NGS costs and scalable barcoding methods make these studies affordable at the scale of millions or billions of cells, with Parse Biosciences' GigaLab service able to process 2.5 billion cells per year. Demand for training data for AI models that predict cell responses, often called virtual cell models, is a newer driver, and Merck plans to use Billion Cell Atlas data to build foundation models.Genome-wide CRISPR and single-cell perturbation studies are expensive, which limits their use by smaller academic laboratories, early-stage biotechnology firms, and institutions in emerging economies that often fall back on targeted screens or outsourcing. Academic budgets are under pressure, with tools makers such as Bruker and Quanterix reporting soft U.S. academic demand in 2026, which can delay instrument purchases and large projects. Data handling is a major challenge, since petabyte-scale datasets need accelerated processing, cloud infrastructure, and bioinformatics skills that many laboratories lack. Screening results can also vary with cell models, guide design, and analysis methods, off-target effects can create false positives, and findings in cell lines do not always carry over to human biology.
Services and data products offer a significant opportunity, as many drug developers would rather buy large screening and single-cell datasets than build the capability in house; the Billion Cell Atlas is the first data product of Illumina's BioInsight business. Variant-to-function work is another opening, as base editing screens, saturation genome editing, and massively parallel reporter assays can test thousands of variants of uncertain significance at once. Cell and gene therapy developers use CRISPR screens to improve the persistence, potency, and safety of engineered cells, and research spending in China, Japan, South Korea, Singapore, and India is rising. Key trends include the scaling of single-cell studies to billions of cells, consolidation among single-cell and CRISPR technology providers, and the use of perturbation data to train predictive AI models.
Segment Analysis
The report analyzes the market by offering, technology, technique, application, end user, and geography, helping stakeholders identify the most attractive areas for product development, partnering, and investment.By offering, the functional genomics market is segmented into kits & reagents, instruments, software & bioinformatics, and services. Kits & reagents are expected to account for the largest share in 2026, as reagents, guide and RNAi libraries, and single-cell and PCR kits are used up in every experiment, and a large installed base of sequencers and PCR systems keeps reagent demand recurring. Services are expected to grow at the highest CAGR, driven by the outsourcing of large CRISPR and single-cell studies, high-capacity offerings such as the Parse Biosciences GigaLab, and the launch of data products such as the Billion Cell Atlas. Software & bioinformatics is also set for strong growth as datasets get larger and AI tools enter routine analysis.
By technology, the functional genomics market is segmented into next-generation sequencing (NGS), PCR & qPCR, microarrays, CRISPR-based technologies, RNA interference (RNAi), and other technologies. NGS is set to hold the largest share in 2026, as RNA sequencing, single-cell sequencing, and epigenomic profiling all depend on it and sequencing is the readout for most large CRISPR and perturbation screens. CRISPR-based technologies are expected to grow at the highest CAGR, supported by wider use of genome-wide knockout, interference, and activation screens, single-cell perturbation projects such as the Billion Cell Atlas, and base and prime editing for variant-level studies. RNAi and microarrays are expected to grow more slowly as researchers move to CRISPR and sequencing-based methods.
By technique, the functional genomics market is segmented into gene expression profiling, genetic perturbation screening, epigenomic profiling, single-cell functional genomics, and other techniques. Gene expression profiling is expected to account for the largest share in 2026, given the broad use of RNA sequencing and qPCR in basic research, drug discovery, and biomarker work, and the role of qPCR in validating expression changes. Single-cell functional genomics is expected to grow at the highest CAGR, driven by studies that now reach millions and billions of cells, the pairing of single-cell readouts with CRISPR perturbations, and consolidation such as QIAGEN's agreement to buy Parse Biosciences and 10x Genomics' agreement to buy Scale Biosciences. Epigenomic profiling shows how gene regulation shifts in cancer and immune disease.
By application, the functional genomics market is segmented into drug discovery & target validation, disease mechanism research, biomarker discovery, cell & gene therapy development, agricultural & synthetic biology research, and other applications. Drug discovery & target validation is expected to account for the largest share in 2026, as drug developers rely on functional genomics to find and confirm targets and explain how drugs work, as the drug company backing of the Billion Cell Atlas shows. Cell & gene therapy development is expected to grow at the highest CAGR, supported by CRISPR screens that improve engineered cell therapies, transcriptomic characterization of cell products, and a growing therapy pipeline. The same tools help improve crops and microbial strains.
By end user, the functional genomics market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, contract research organizations, and other end users. Academic & research institutes are expected to account for the largest share in 2026, as universities, research institutes, and government programs such as MorPhiC carry out much of the field's research. Pharmaceutical & biotechnology companies are expected to grow at the highest CAGR, driven by target work, AI-led discovery, and cell and gene therapy programs, while funding pressure is expected to slow growth in the academic segment. CROs gain as more screening work is outsourced.
Regional Analysis
The report covers North America, Asia-Pacific, Europe, Latin America, and the Middle East & Africa, spanning 20 countries and four rest-of-region groups. The regional analysis of the functional genomics market considers research funding, pharmaceutical R&D, genome centers, precision medicine programs, and supplier presence.North America is set to hold the largest share of the functional genomics market in 2026, owing to strong public and private research funding, leading research institutions and genome centers, a dense base of drug developers, and home-based suppliers such as Illumina, 10x Genomics, Thermo Fisher Scientific, Bio-Rad Laboratories, Integrated DNA Technologies, and Agilent Technologies. In the U.S., demand is supported by programs such as MorPhiC and industry projects such as the Billion Cell Atlas, although weaker academic funding may slow near-term growth, while Canada adds demand through academic genomics and a growing AI drug discovery sector. Europe holds a significant share, supported by strong academic research, large pharmaceutical companies, and suppliers such as Merck KGaA and QIAGEN; the U.K. stands out for its genome research centers and pharmaceutical R&D, and Germany, Switzerland, France, the Netherlands, Sweden, and Denmark also contribute.
Asia-Pacific is projected to post the highest CAGR through 2036, owing to rising R&D spending, growing biopharmaceutical industries, national precision medicine programs, and local service and reagent suppliers. China is expected to hold the largest share in the region, helped by heavy life science investment and a large services base, while Japan, home to Takara Bio, is a key market for expression and editing tools, and South Korea, Singapore, Australia, and India are set for strong growth. Latin America, led by Brazil and Mexico, and the Middle East & Africa, where Saudi Arabia, the UAE, and Qatar run genomic medicine programs, hold smaller shares.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard, and market share/rank analysis by key player for 2025, together with company profiles covering business and financial overviews, functional genomics portfolios, strategic developments, and SWOT analyses.The functional genomics market is moderately consolidated, as large life science tools companies with sequencing, PCR, and reagent portfolios compete with specialists in CRISPR tools, single-cell platforms, analysis software, and services. Competition centers on throughput, cost per cell or sample, data quality, the range of reagents and libraries, end-to-end workflows, software and AI capabilities, and global support. Recent developments include 10x Genomics' August 2025 agreement to acquire Scale Biosciences, the July 2025 purchase of Synthego by funds managed by Perceptive Advisors, QIAGEN's November 2025 agreement to acquire Parse Biosciences, the January 2026 launch of the Illumina Billion Cell Atlas, and the April 2026 launch of the 10x Genomics Atera spatial biology platform.
Key companies profiled in the report include Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), QIAGEN N.V. (Netherlands), Bio-Rad Laboratories, Inc. (U.S.), 10x Genomics, Inc. (U.S.), Revvity, Inc. (U.S.), Merck KGaA (Germany), Danaher Corporation (Integrated DNA Technologies) (U.S.), Takara Bio Inc. (Japan), and GenScript Biotech Corporation (China).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global functional genomics market.
- Explains how drug target discovery, CRISPR screening, single-cell perturbation, and AI training data are driving demand.
- Assesses the impact of study costs, academic funding pressure, data complexity, and reproducibility on the market.
- Identifies high-growth opportunities across offering, technology, technique, application, end user, and region.
- Tracks data products, variant-to-function assays, and CRISPR tools for cell therapy.
- Benchmarks leading companies by portfolio breadth, throughput, cost per cell, acquisitions, and partnerships.
- Supports product planning, partnering, and market entry decisions for suppliers and investors.
Key Questions Answered
- How big is the global functional genomics market today, and how will it grow through 2036?
- How are CRISPR screening and single-cell perturbation changing drug target discovery?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How will demand for AI training data and virtual cell models affect the market?
- Which offering, technology, technique, application, and end user segments will grow the fastest?
- How fast is CRISPR replacing RNAi in functional screening?
- What do recent single-cell and CRISPR acquisitions mean for the competitive landscape?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading companies in the market, and what strategies are they using?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. Functional Genomics Market, by Offering
6. Functional Genomics Market, by Technology
7. Functional Genomics Market, by Technique
8. Functional Genomics Market, by Application
9. Functional Genomics Market, by End User
10. Functional Genomics Market, by Geography
11. Competitive Landscape
12. Company Profiles
13. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- Agilent Technologies, Inc.
- QIAGEN N.V.
- Bio-Rad Laboratories, Inc.
- 10x Genomics, Inc.
- Revvity, Inc.
- Merck KGaA
- Danaher Corporation
- Takara Bio Inc.
- GenScript Biotech Corporation
